SCHEMBL2593282

SCHEMBL2593282

CCC(CC)OC(=O)C1(COc2c(-c3ccc4c(c3)CNC4=O)ccc(OC)c2OC)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLQ O75417 1/20 0.35
TDP2 O95551 2/20 0.35
MAPKAPK2 P49137 1/20 0.35
GSK3B P49841 2/20 0.34
DAPK3 O43293 1/20 0.34
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
FLT3 P36888 1/20 0.34
ROCK1 Q13464 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
PRKCI P41743 1/20 0.33
PDE4D Q08499 2/20 0.33
PRF1 P14222 2/20 0.33
BRAF P15056 1/20 0.32
TARS1 P26639 1/20 0.32
KIT P10721 1/20 0.31
ADORA1 P30542 1/20 0.31
AKT1 P31749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591908 0.97 POLQ (0.34) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL14736905 0.92 PDE4D (0.40) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL14736778 0.92 PDE4D (0.40) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL2592943 0.91 PDE4D (0.37) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL2591397 0.89 POLQ (0.40) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL14737405 0.89 PDE4D (0.39) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL14736815 0.89 PDE4D (0.39) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL2591133 0.89 POLQ (0.38) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL2592267 0.88 PDE4D (0.36) POLQTDP2MAPKAPK2GSK3BDAPK3
SCHEMBL2588539 0.87 PDE4D (0.38) POLQTDP2MAPKAPK2GSK3BDAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A POLQ 1717/4885TDP2 54/4885MAPKAPK2 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.